SCHEDULE: Deep Track Capital Amends Bicycle Therapeutics Stake
Schedule 13G Amendment
Deep Track Capital, LP and affiliates filed an amendment to their Schedule 13G, reporting a 2.42% beneficial ownership in Bicycle Therapeutics plc.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed Amendment No. 5 to their Schedule 13G.
- The reporting persons collectively beneficially own 1,203,244 American Depositary Shares of Bicycle Therapeutics plc.
- This ownership represents 2.42% of the class of securities.
- The shares are held with shared voting power and shared dispositive power.
- The beneficial ownership calculation is based on 49,816,000 Ordinary Shares, which includes 47,761,845 Ordinary Shares outstanding as of April 28, 2025, and 2,054,155 non-voting ordinary shares converted by the reporting person.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory update.
Risks
- The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment firm in a biotechnology company. It reflects an ongoing investment position rather than a new strategic move or significant change in the company's operational landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which is now below the 5% threshold for mandatory annual Schedule 13G filings.
Key Dates
| Date | Description |
|---|---|
| 2025-04-28 | Date of Ordinary Shares outstanding used for beneficial ownership calculation (47,761,845 shares). |
| 2025-05-01 | Date of issuer's 10-Q filing with the SEC, which provided the outstanding share count. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-14 | Date of signing for Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. |
Keywords
Bicycle Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, ADS, Biotechnology, Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.